Navitoclax Safety, Tolerability, and Effect on Biomarkers of Senescence and Neurodegeneration in Aged Nonhuman Primates
Edward Greenberg(AbbVie (United States)), Hana Florian(AbbVie (United States)), David R. Reuter(AbbVie (United States)), Suzanne E. Ybarra(AbbVie (United States)), Yuchuan Zhuang(AbbVie (United States)), Mathias Droescher(AbbVie (Germany)), Kennan C. Marsh(AbbVie (United States)), Elizabeth Asque(AbbVie (United States)), J Mollon(AbbVie (Germany)), Min Hu(Central China Normal University), Karin Orsi(AbbVie (United States)), Vivian Zhao(AbbVie (United States)), Alexandra A. Smith(AbbVie (United States)), Susan V. Westmoreland(Harvard University), Joseph S. Spina(Northeastern University), Ryan Duggan(AbbVie (United States)), Sjoerd J. Finnema(Itron (United States)), Carolin Hoft(AbbVie (Germany)), Dustin Wooten(AbbVie (United States)), Yupeng He(Guardant (United States)), Y. K. Fang(AbbVie (United States)), Aparna Vasanthakumar(University of Chicago), Willi Amberg(AbbVie (Germany)), Matthew Townsend(AbbVie (United States)), Heather Knight(AbbVie (United States)), Martin J. Voorbach(AbbVie (United States)), Lori Duggan(AbbVie (United States)), Karen Dalecki(AbbVie (United States))
Cited by 0
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
|Clinical Cancer Research|2021|369